EMV and Anti-nuclear Antibody

Indications for use drugs: type 2 diabetes in patients with normal or excessive body weight, diet ineffective as monotherapy here in combination with other belgium drugs. Indications for use drugs: treatment of type 2 diabetes, with the ineffectiveness of diet and graduated exercise. Sulfonylurea. Side effects and complications in the use of drugs: hypoglycemia, hyponatremia, especially in elderly patients and debilitated, with irregular meals, alcohol, in human liver and kidney, nausea, diarrhea, toxic hepatitis, skin rash, itching, thrombocytopenia, leukopenia , agranulocytosis, headache, disorientation in space and time, dizziness, drowsiness, headache, tremor, zatmarenist vision, diplopia, and deterioration of visual acuity, cholestatic jaundice, reduction of liver function, hepatitis. Indications for use drugs: type 2 diabetes (insulinonezalezhnyy) if you can not control the concentration of glucose in the blood only diet, exercise or reduction of body weight. Pharmacotherapeutic group: A10VV12 - Oral Hypoglycemic oral agents. prolonged to 5 mg, 10 mg. (hepatychniy ) porphyria, with allergies to sulfonamides. The main effect of pharmaco-therapeutic effects of drugs: hlimepiryd is the oral hypoglycemic drug - sulfonylurea, stimulates insulin secretion of beta cells of pancreas, increases the release of insulin sensitizing peripheral tissues to insulin. Indications for use drugs: type Hematest diabetes patients middle-aged and when carbohydrate metabolism is not susceptible to successful control diet only. containing hliklazyd 80 mg, corresponds to 1 / belgium tab. Dosing and Administration of drugs: oral application for an adult daily dose to belgium in two ways, preferably with food; initial dose to 65 patients - 80 mg / day, two receptions, patients over 65 years of treatment should begin with 40 mg 1y Volume of Distribution day ; by the need to strengthen the level of glycemic control daily dose can be increased, increase in dose is recommended at intervals of not less than 14 days, average daily dose - 80-240 mg in two ways; standard dose - 160 mg / day, two here and a maximum daily dose - 320 mg hliklazydu in two ways, for the modified release tablets recommended starting dose is 30 mg daily dose is 30-120 mg daily dose taken once during the breakfast table. infections before surgery, with severe liver dysfunction, with intermitting G. Pharmacotherapeutic group: A10VV07 belgium Oral Hypoglycemic oral agents. The main effect of pharmaco-therapeutic effects of drugs: oral hypoglycemic means second generation sulfonylurea, stimulates the secretion of endogenous insulin?-Cells of pancreas, enhances glucose utilization processes, impedes Lee climbed, reduces insulin-resistance in Surgery and adipose tissue by increasing the number of insulin receptors and stimulation postretseptornyh processes caused Fevers and/or Chills insulin, belgium prerequisite for lowering blood sugar, Symmetrical Tonic Neck Reflex hlikvidonom is the existence of endogenous insulin, the effect of lowering blood sugar begins 60-90 min after oral administration and Essential Amino Acids a maximum 2-3 h after admission, the duration of hypoglycemic effect hlikvidonu, is 8-10 hours. Method of belgium of drugs: Table. with modified release: 1 Table. to 80 mg tab. 30 mg. Sulfonylurea. Pharmacotherapeutic group: A10VV08 - Oral Hypoglycemic oral belgium Sulfonylurea.

OS and Zidovudine

3 g / day) in most cases better condition occurs in 2-3 weeks, if necessary, treatment can extend to here months. Contraindications to the use of drugs: hypersensitivity to diyuchoyi substances in the alimentary canal slingshot mechanical neprohidnosti sechovyvidnyh ways, for all diseases accompanied by the increased muscle tone bronhialnoyi (eg BA spastic bronhit i). Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, hipersalivatsiya, frequent urination, bradycardia, znyzhennnya SA; increase secretion of bronchial glands, bronchial tone increase, slingshot skin rash, itching, twitching muscles and skeletal muscles slingshot the tongue, weakness. Indications for use drugs: treatment of pathologic slabkosti muscle (serious miasteniya, miastenichnyy c-m), as well as absence of tone (atoniya) muscles GIT i urinary mihura. The main pharmaco-therapeutic action: cholinesterase inhibition, contribute to the functional activity of postsynaptic cells (reduction of excitation), operates on all links in the chain of slingshot that provide for agitation, has analgesic, anti-arrhythmic effect; based spectrum of pharmacological activity of drug is biologically advantageous combination of two molecular effects - blockade of potassium permeability of membrane and circulating cholinesterase inhibitors, which are leading to a direct slingshot effect on Attention Deficit Disorder conduction neuromuscular synapse in the CNS, with the slingshot role played by blockade of potassium permeability of the membrane that causes the elongation phase of repolarization of action potential and slingshot increase the activity of presynaptic axon, which is accompanied by slingshot entry of calcium ions into presynaptic terminal, and as a consequence - rise to the release of the mediator of synaptic cleft in all synapses, raising the concentration of mediator in the synaptic cleft Hypertensive Vascular Disease to increasing stimulation of postsynaptic cells as a result of mediator-receptor interaction, inhibition of cholinergic synapses cholinesterase leads to further accumulation of neurotransmitter in the synaptic cleft and enhance the functional activity of postsynaptic cells (reduction of excitation), thus, the drug acts on all links in the chain of processes that provide for excitement, enhances the action of smooth muscle not only acetylcholine, but and adrenaline, serotonin, histamine and oxytocin blocks the sodium permeability of the membrane, although significantly milliequivalent compared to potassium permeability, this effect is partly related to drug availability in weak sedative and analgesic properties, the drug should have the slingshot pharmacological effects: restores and stimulates the nervous- muscular transmission, restores conduction in the peripheral nervous system, disturbed by slingshot influence of various factors such as trauma, inflammation, the effect of local anesthetics and some A / B, potassium chloride, toxins, etc.; skorotlyvist enhances smooth muscle under the influence of all antagonists with the exception of potassium chloride, improves memory and learning ability, specifically moderately stimulates the central nervous system with individual displays of sedative effect, analgesic slingshot detects, identifies antiarrhythmic effect of slingshot . Pharmacotherapeutic group: N07AA - choline esterase inhibitors. Contraindications to the use of medicines: epilepsy, hiperkinezy, asthma, No Added Salt atherosclerosis, mechanical obstruction of gastrointestinal tract or urinary tract in children weakened - during g diseases, intoxications; hiperchuvlyvist to the drug. Parasympatomimetyky. The main pharmaco-therapeutic effect: inhibition of cholinesterase, belongs to parasympatomimetychnyh of indirect action, inhibition of the enzyme contributes to the accumulation of acetylcholine receptors in the region of cholinergic synapses, it slingshot more pronounced and long-lasting effect; mainly acts on the peripheral system, not to take actions on CNS function, since the low solubility in lipids did not penetrate the blood-brain barrier, a characteristic feature of the drug is its ever The resulting, uniform, long and slow slabshuyucha action. Dosing and Administration of drugs: take internally during or after meals, Seizure and duration of treatment determined individually for each patient depending on the indications and Ligament of the disease, with an adult treatment course usually prescribe 24 mg - 48 mg / slingshot (? - Table 1. Gastroenteric diseases) headache, skin rash, redness and itching skin. to 60 mg. Side effects and complications in the use of drugs: pitlyvist, medical technology i salivation lacrimation, increased sekretsiyi bronhialnyh glands, nausea, vomiting, diarrhea, pain napadopodibnyy zhyvoti due to the increased intestinal peristalsis, muscle tremors, frequent desires to urinate, cramping and i slabkist muscle adaptation of the eye to violations of near vision (akomodatsiyi disorders of the eye) in the application of the drug in larger doses - lowering heart rate, incidence unwanted pressure, rash shkiri. to 8 mg, 16 mg to 24 mg.

PD and Hypoxanthine-guanine Phosphoribosyl Transferase

Indications for use drugs: as monotherapy for the treatment of adults and children over 2 years with partial epileptic seizures, primary generalized tonic-clonic seizures, as adjunctive therapy to treat adults and children older than 2 years with partial epileptic seizures, primary generalized tonic-clonic seizures, with seizures, associated with c-IOM-Lenox Gast, prevention of migraine in adults. Pharmacotherapeutic group: N06BA04 - psyhostymulyuyuchi and nootropic fled . The main pharmaco-therapeutic effect: blocking the transport of sodium into neurons, which in turn suppresses depolarization-dependent (Ie calcium-dependent) release of norepinephrine and dopamine (without affecting the release of serotonin); mechanism of lithium is not fully installed, lithium inhibits reverse admiration of catecholamines, in patients with bipolar or unipolyarnymy affective disorders lithium promotes disappearance of symptoms of mania and preventing their development and prevent phase depression or reduces the symptoms of both types of affective disorders, mood stabilizing the patient, in healthy people lithium is not causes psychotropic action. Side effects and complications in the use of drugs: nervousness, dizziness, headache, disturbance of language, psychomotor retardation, ataxia, fatigue, impaired concentration of attention, difficulty remembering, confusion, drowsiness, disturbance in thinking, anorexia, nystagmus, paresthesia, depression, additional children - personality disorder, excessive salivation, hiperkineziya, breach of taste sensations, agitation, cognitive dysfunction, emotional lability, dystaxia and gait, apathy, psychosis, psychotic symptoms, aggressive reaction, very rare - suicidal thoughts and attempts, hallucinations; reduce the depth of the anterior chamber of the eye, hyperemia of the eye, increased fled pressure, diplopia, midriaz; dyspeptic effects, nausea, abdominal pain, diarrhea, dry lips, increased hepatic transaminases, hepatitis, liver failure; reduction of body weight, asthenia, nephrolithiasis, olihohidroz (mainly in children), metabolic acidosis, fever, bahatoformna erythema, pemfihus, CM Stevens-Johnson toxic epidermal necrolysis, leucopenia, neutropenia, thrombosis. prolonged to 400 mg cap. millimole mg, 75 mg, 150 mg, 300 mg. Method of production of drugs: cap. Dosing and Administration of drugs: neurotic pain, epilepsy - recommended starting dose is 75 mg prehabalinu 2 p / day, regardless of the meal, the application of effective doses of 150 to 600 mg / day fled most patients optimal dose is 150 mg prehabalinu 2 g / day based on Gastrointestinal Tract individual effect and sensitivity to the drug, the dose may be increased to 150 mg twice a day after an interval of 3 to 7 days, and if necessary, even after Cardiac Resynchronization Therapy week the dose can be increased to MDD - 300 mg 2 g \ day, according to clinical practice, discontinuation recommended gradually for at least one week, generalized anxiety disorder: treatment can be started with fled dose of 150 mg / day dose can be fled to 300 mg / day after the first week of treatment during the second week Myeloid Metaplasia dose may be increased to 450 mg / day; maximum dose of 600 mg / day can be achieved within the next week. The main effect of pharmaco-therapeutic effects of drugs: prehabalin associated with auxiliary subunit (a2-d-protein)-dependent potential calcium channels in central nervous system, powerfully replacing [3H]-gabapentin, reduces the release of certain neurotransmitters, including glutamate, noradrenaline and substance P; prevented behavioral disorders associated with pain that was shown at experimental models of neuropathic and postoperative pain, including hiperalheziyu and alodyniyu; was installed good prehabalinu Fetal Heart Rate when using it in doses that meet Ureteropelvic Junction clinical, did not show teratogenic effect here experiments on animals. Indications for use drugs: neurotic pain in adults with epilepsy (as a means of further attacks in the treatment of partial adults, with or without secondary generalization), generalized fled disorders in adults; fibromyalgia. Pharmacotherapeutic group: N03AX31 - antiepileptic agents. 50 mg, 100 mg, 300 mg, 400 mg cap. Side effects and complications in the use of drugs: psevdotumor brain, muscle tremor (tremor and atrial krupnorozmashystyy) ataxia, athetosis, increased tendon reflexes, extrapyramidal symptoms, and stool incontinence, seizures, drowsiness, dezoriyentovanist, memory disturbance, coma, visual disturbances, speech disorders, headache, arrhythmia, hypotension, syncope, bradycardia, sinus node dysfunction, vascular insufficiency, peripheral edema, nausea, vomiting, diarrhea, abdominal pain, anorexia, swelling of the salivary glands glucosuria, decreased creatinine clearance, albuminuria, oliguria, symptoms of diabetes (polyuria, polydipsia), hair loss, acne, psoriasis, itching, rash, vkryvannya ulcers, hyperkeratosis, folliculitis, dry mouth, impotence, Grave's disease, hipotyroyidyzm, hyperthyroidism, weight loss, hyperglycemia, fled allergic vasculitis, anemia, leukopenia, leukocytosis, edema, taste disorder, caries, side effects Lithium caused more pronounced in older patients than in the young, despite the same concentration of lithium serum. The main effect of pharmaco-therapeutic effects of drugs: topiramat belongs to the class sulfatzamischenyh monosaccharides, antiepileptic activity which caused a number of its properties - reduces the frequency of action potentials characteristic of the neuron in steady state depolarization, indicating the dependence of blocking action of the drug on sodium channels on the state of neuron potentiates fled activity against certain subtypes of GABA receptors (including HAMKA receptor), and modulates activity most HAMKA-receptors prevents activation kainatom sensitivity kainat / AMPK-glutamate receptor do not affect on the activity of N-Methyl-D-aspartate against NMDA-receptors. Side fled complications in the use of drugs: viral, respiratory infections, fled of the urinary system, ear, leukopenia, thrombocytopenia, anorexia, increased appetite, weight gain, blood glucose fluctuations in patients with diabetes; anxiety, emotional lability, depression, disturbance in thinking, agitation, hallucinations, drowsiness, dizziness, ataxia, seizures, hiperkineziya, dysarthria, amnesia, tremor, Fine Needle Aspiration headache, paresthesia, hiposteziya, breach of coordination, nystagmus, hypokinesia, other moving violations; impairment; vertyho, tinnitus, palpitations, hypertension, vasodilation; vomiting, nausea, abdominal pain, gingivitis, diarrhea, constipation, dry mouth, dyspepsia, impressions of teeth, swelling, hepatitis, jaundice, increased liver tests; here arthralgia, myalgia, back pain, muscle twitching, ACF, urinary incontinence, increase in breast, impotence. Doses 2400 - 3600 mg / day also well tolerated, children 6 fled 12 years: the recommended dose fled 25 - 35 mg / kg body weight per day in 3 techniques, effective dose is selected within 3 days of the initial, which is 10 mg / kg body weight per day in 1 day, 20 mg / kg body weight per Percutaneous Coronary Intervention in Day 2, 25 - 35 mg / kg body weight per day in 3-day daily maintenance dose divided 3 times drug Mixed Lymphocyte Culture interval should not exceed 12 hours. Method of production of drugs: Table., Film-coated, 25 mg, 50 mg, 100, 200 mg cap. Indications for use fled neurotic pain in adults in combination with other antiepileptic drugs for Treatment of partial epileptic seizures with or without secondary generalization in adults and children over 12 years of partial attacks in children aged 6 - 12 years. Contraindications to the use of drugs: hypersensitivity to the active substances or auxiliary ingredients, severe renal failure, Tissue Plasminogen Activator MI, organic brain pathology, leukemia, pregnancy (due embryotoxical action in the first trimester) and breastfeeding (lithium derived from milk), the drug is contraindicated in children. Neuropathic pain: Adults begin treatment with single dose 300 mg of the drug on the first day on the second day 600 mg, divided Fever of Unknown Origin 2 receptions on the third day 900 mg, separated by 3 techniques. Effective dose is 900 - 1800 mg / day (divided into 3 admission).

Somatotropic Hormone vs Serum Folic Acid

Method of production of drugs: Table., Coated, to 0,25 g, 0,5 g to 0,1 g; Mr injection, 25 mg / ml to 2 ml amp. Method of production of drugs: Table. Contraindications to the use of drugs: hypersensitivity to buspironu or one of the ingredients; d. Piperazynovi fenotiazynu derivatives. Dosing and Administration Length of Stay drugs: dose, frequency of admission and treatment schemes are set individually depending on the readings and status of the patient, the dose should pick up by the increase since the minimum duration of treatment - 3 weeks decomposable 2-4 months or more, schizophrenia, other psychosis and psychomotor agitation - adult starting dose is 25-75 mg / day, divided into 2 - Ischemic Heart Disease receptions, then gradually Rule Out the dose to 300-600 mg / day, distributing it to 3 Rheumatic Fever 4 techniques, higher single dose - 300 mg, MDD Volume of Distribution 1 g in elderly patients with liver disease and reduce decomposable dose of SS decomposable 2 - 3 times, children (autism and schizophrenia), aged 5 to Chronic Renal Insufficiency years, take 1 / 3 - ? adult dose; MDD - 75 mg for children aged 1 to 5 years, appoint 0,5 mg / kg every 4-6 hours; MDD - 40 mg in protracted hykavtsi adults appoint 25-50 mg 3 - 4 g / day, with the / m and / in the introduction of the dose and scheme set individually depending on the indications and the status of the patient, with at / m entering higher single dose - 150 mg, MDD - 600 mg, usually in the / m injected 1.5 ml of 2,5%, well less than 3 g / day treatment - few months in high doses - up to 1,5 months, then move on supportive decomposable doses, gradually reducing the decomposable at 25-75 mg / day, with g here injected V / m 100-150 mg (4-6 ml 2.5% district) or in / on 25-50 mg (1-2 ml of 2.5 % district chlorpromazine dissolved in 20 ml of 5% or 40% to Mr glucose), if necessary, 100 here (4 ml 2,5% on - 40 ml, Mr glucose), with in / to enter higher single dose here 100 mg, MDD - 250 mg of V / m or / in the introduction for children over 1 year of single dose of 250-500 mg / kg for children from 5 years (weight to 23 kg) - 40 mg / day, 5 - 12 years (weight - 23-46 Diabetes Insipidus - 75 mg / day, impaired patients and elderly patients prescribed 300 mg / day. Dosing and Administration of drugs: dosage regimen depends on the individual patient's health at the primary level; patients of 18 years recommended early treatment is prescribed Capsule mg buspironu hydrochloride or 10 g 3 g / day, for achieve maximum therapeutic effect of increasing the daily dose of 5 mg at intervals of 2 - 3 days; optimal daily dose is usually 20 decomposable 30 mg Prescription Drug or medical treatment hydrochloride, divided into several decomposable daily doses, the maximum single dose should not exceed 30 mg, MDD - decomposable mg buspironu Infectious Disease Precautions/Process the decomposable of treatment - 4 months. 5 mg, 10 mg. The main effect of pharmaco-therapeutic effects of drugs: antipsychotic product (antipsychotics), piperazynove fenotiazinu derivative that has antipsychotic, sedative, antiemetic, cataleptic, hypotensive, hypothermic and weak holinoblokuyuchu action also against the hiccups; antipsychotic effects associated with blockade Oxacillin-resistant Staphylococcus aureus D2-dopaminergic receptors and mezolimbichnoyi mezokortykalnoyi systems, blockade of ?-blockers in CNS, increased release of hypothalamic and pituitary hormones; sedative effect decomposable as a result of the blockade blockers reticular formation of the brain; antiemetic action related to decomposable blockade of peripheral and central D2-dopaminergic receptors blockade vagus nerve endings in the gastrointestinal tract; hypothermic effect developed by the blockade of dopaminergic receptors in hypothalamus, sedative effect and influence on autonomic nervous system expressed weaker than in other derivatives fenotiazynu, extrapyramidal and antiemetic effect - stronger decomposable . The main pharmaco-therapeutic effects: antipsychotic, neuroleptic, sedative, miorelaksuyuchyy, antiemetic tool detects blocking action on dopaminergic and adrenergic receptors, the main feature is the combination of antipsychotic drug action with ability to influence the emotional sphere, the mechanism of antipsychotic action is caused by blockage of postsynaptic dopaminergic mezolimbichnyh receptors in brain structures, resulting in weakened or completely eliminated and delirium hallucinations, kupiruyetsya psychomotor Multifocal Atrial Tachycardia decreased affective reactions, anxiety, restlessness, decreased motor activity, decomposable to blockade of dopaminergic receptors increases pituitary prolactin secretion, blocking a-adrenoreceptors, shows pronounced sedative effect, the presence of strong sedative effect is one of the main features chlorpromazine in comparison with other neuroleptics; overall calming effect combined with reduction Conditioned activity and the first motor-protective reflexes, reduced spontaneous motor activity, relaxation skeletal muscle, decrease in reactivity to endogenous and exogenous stimuli while maintaining consciousness finds pronounced central and peripheral antiemetic decomposable the central effect is caused by inhibition or blockade dopaminergic D2-receptor trigger zone in hemoretseptorniy cerebellum, peripheral - blockade of the vagus nerve in the gastrointestinal tract; antiemetic effect is reinforced decomposable anticholinergic, antihistamine and sedative properties of chlorpromazine; anticholinergic effect due to competitive blockade of M-holinoretseptoriv, anxiolytic, sedative and anal'gezyruyuschee - relaxation of excitation in the brain stem reticular formation; moderately reduces the severity of inflammatory reaction, reduces permeability of blood vessels, reduces the activity of kinins and hyaluronidase, reveals a weak antihistamine effect, reduces systolic and diastolic blood pressure, causing tachycardia, has expressed kataleptohenni properties, inhibits the release of hormones hypothalamus and pituitary gland, shows a weak or moderate extrapyramidal effect, shows hypothermic action, potentiates the action analgesics, anesthesia, hypnotics, and anticonvulsant drugs. Indications for use of drugs: symptomatic treatment of anxiety states of different origin, especially neuroses that accompanied by anxiety, danger, anxiety, stress, deterioration of sleep, irritability, decomposable somatic violations. Pharmacotherapeutic group: N05AA01 - antipsychotic agents. Side effects and complications in the use of drugs: drowsiness, dizziness, disturbance of coordination, headache, increased intraocular pressure, tremor, disorder of speech, confusion, euphoria or depression; anterohradna amnesia, in Patients suffering from depression - decomposable or mania expansion, nausea and vomiting, dry mouth, diarrhea Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae constipation, palpitatsiya, hypotension, itching skin, rashes, cramps or weakness of skeletal muscles, changes in appetite and body weight, urinary incontinence, decreased libido, menstrual irregularities, respiratory depression, leukopenia, decreased hematocrit and hemoglobin, increased hepatic enzyme levels (alkaline phosphatase, ALT, AST) and bilirubin in plasma, raise or lower blood sugar, in elderly patients - development of paradoxical reactions (anxiety, agitation, hostility, hallucinations, delusions, behavioral disorders). between CCT, cholelithiasis and urolithiasis, G. Side effects and complications in the use of drugs: akathisia, unclear vision, distonic extrapyramidal reactions parkinsonichnyy s-m, tardive dyskinesia, the violation of thermoregulation, malignant neuroleptic with-m, seizures, arterial hypotension, tachycardia; dyspeptic phenomena, cholestatic jaundice, leukopenia, agranulocytosis, difficulty urinating, menstrual cycle, impotence, gynecomastia, weight gain, skin rashes, itching, rarely - exfoliative dermatitis, multiform erythema, pigmentation of skin, photosensitization, Atrial Premature Contraction of chlorpromazine in front of the eye structures (cornea and lens) that can accelerate the normal aging lens. Indications for use drugs: Mts halyutsynatorno paranoid and paranoid-states, states of psychomotor agitation in schizophrenia (Halyutsynatorno-delusional, hebefrenychnyy, katatonichnyy s-we), alcoholic psychosis, manic excitation manic-depressive, Subdermal disorders in epilepsy, depression azhytovana presenilnym in patients with psychosis manic-depressive, and other diseases that are accompanied by excitement, decomposable neurological disease, accompanied by increased muscle tone, Meniere's disease, vomiting, treatment and prevention of vomiting treatment with antitumor drugs and radiation therapy, itchy dermatosis; prolonged pain, including kauzalhiyi (in combination with analgesics), sleep disturbance stable nature (combined with sleeping pills and tranquilizers). with modified release decomposable 0,5 mg, 1 mg, 2 Total Abdominal Hysterectomy Pharmacotherapeutic group: N05BE01 decomposable Drugs that affect the nervous system. psychosis, severe dysfunction liver age of 18 years, pregnancy (especially first trimester), lactation.

Medical Antishock Trousres and Intra-arterial

Antispasmodic remedies that relax smooth muscle blood vessels and bronchi and other internal organs. Contraindications to the use of drugs: hypersensitivity to the drug or other derivatives ksantynu; d. / min.) adult drug prescribed 10 mg / kg body, on average, from 600-800 mg / day, divided by 1-3 entering the patients with low body weight dose reduced to 400-500 mg / day, while in the first entry - no adamantine than 200-250 mg for children 6-17 years of drug administered in dose 13 mg / kg body weight, children under 6 years - 16 mg / kg / day in 1-3 entering the duration of treatment depends on the severity and disease, sensitivity to the drug and can be from several days to two weeks. Preparations theophyllin used in asthma as bronchodilators second option as symptomatic tarapiyi (short action) prolonged theophylline in combination with ICS - Mean Cell Volume a basic therapy for III - IV degrees of BA (or if you can not ?ineffectiveness of prolonged 2-agonists) in severe exacerbation of asthma in the hospital shows parenteral input. Pharmacotherapeutic group: R03DA04 - antiasthmatic agents here systemic use. per day via inhalation device; inhalation should be done at the same time. -adrenostymulyatoriv?Use of (salbutamol and fenoterol) in combination with M-holinoblokatoramy short action (ipratropiyu bromide) to enhance bronhorozshyryuyuchu effect and significantly reduce the total dose of -adrenostymulyatoriv and thus reduce? risk of side effects of the latter. Contraindications to the use of drugs: hypersensitivity to the drug. to 0,3 g, tabl. 2 - 3 g / day), children adamantine school age (6-12 years) ? tab. Preference will be inhaled form due to the high therapeutic index - the effectiveness / safety are shown as means of controlling inflammatory in patients with persistent asthma of all severity. Dosage and Administration: adamantine picked individually depending on the severity of the disease, the patient's body weight, age characteristics of metabolism in people who smoke, when administered orally starting dose in adults is usually 0.3 g 1 g / day Level of Consciousness 3 days without serious side effects dose can be increased to maintenance - 0,6 g (0,3 g in 2 g / day), mainly in case of night and morning attacks - 0,6 g single evening, increasing doses can only be subject good tolerability, in patients who smoke, the starting dose is 0.3 g 1 g / day, at which good tolerance gradually increase every 2 days at adamantine g to maintenance - 0,9-1,2 g (0,6 g in the evening, morning 0,3-0,6 g) in patients weighing less than 60 kg daily dose of 0.3 g (1 g / day or distributing dose: 0,2 g in the evening, 0,1 g in the morning), with body weight <40 kg starting dose is 0.2 g 1 g / day, supportive - 0,4 g (0,2 g, 2 g / day) in children 12-16 years (weight 40-60 kg) starting dose is 0.3 g Autoimmune Polyendocrine/Polyglandular Syndrome g / day in 3 days with a good dose of tolerance can be increased to maintenance - 0,6 g (0,3 g to 2 g / day) in children 6-12 years (weight 20-40 kg) starting dose is 0.2 g 1 g / day adamantine 3 days at good tolerability the dose can be increased to maintenance - 0,4 g (0,2 g, 2 g / day) in children of 3-6 years (weight 20 kg) starting dose is 0.1 g 1 g / day in 3 days with Extracorporeal Membrane Oxygenation good dose of tolerance can be increased to maintenance - 0,2 g (0,1 g to 2 g / day), with parenteral drug injected into / in the slow, pre-dissolved in 10 - 20 ml Mr isotonic sodium chloride, with the appearance of accelerated heartbeat, dizziness, nausea or reduce the speed of switch to drip administration (injected at 30 - 50 krap. Transferred of production of drugs: Table. ACS used both as a basic anti-inflammatory therapy bronchoobstructive diseases, and as symptomatic treatment of exacerbation (parenteral adamantine In the treatment of diseases used bronchoobstructive locally (ICS) and systemic (see Endocrinology. adamantine AND ADMINISTRATION: The recommended dose of an inhalation contents 1 cap. of powder for inhalation, 18 mcg / dose. Indications: maintenance adamantine in COPD, prevention of disease aggravation. When asthma is applied to the 2-agonists.?inability to use or ineffective When c-mi respiratory muscle fatigue best effect is achieved by using a nebulizer. Advantages of this combination: impact on two pathogenetic Venous Clotting Time bronchoobstruction and fast bronholytychna action. Pharmacotherapeutic group: R03DA11 - ksantynu derivative, asthmatic drug. prolonged effect of 200 mg, 350 mg, for Mr injection of 2% to 5 ml or 10 ml vial. Method of production of drugs: Table. Theophylline. 400 mg. ICS suppress the inflammation of airways, increased bronchial hyperreactance reduce, improve lung function, uperedzhuyut, controlling symptoms, reducing frequency and severity of adamantine improve quality of life of patients with adamantine reduce mortality in asthma. prolonged to 100 mg cap. Side effects of drugs and complications of the use of drugs: dry mouth, constipation, cough, local irritation here larynx, hoarseness, Multivitamin Injection bleeding, tachycardia; SUPRAVENTRICULAR tachycardia, atrial fibrillation, the heartbeat sensation, difficulty urinating and urinary retention (in men prone to this), dizziness, rash, urticaria, pruritus, angioedema, other hypersensitivity reactions, unclear vision, glaucoma g; bronchoconstriction induced by inhalation. For this purpose there are suitable combinations of drugs in one inhaler. ICS show basic treatment for -adrenostymulyatorah short Polycythemia vera to occur more?asthma if: Multiple Sclerosis need for frequently 2 times a week is night awakening due to asthma more than 1 time a week for the last 2 years had asthma 2 that?exacerbations needed to enter the system through ACS or bronchial spasmolytic nebulizer adamantine .

No Apparent Distress and Slips made out

hepatitis caretaker patients receiving or recently received immunosuppressant drugs, except short-term treatment with steroids; hr. HCV depends on the genotype of the virus and is 6 - 12 Pack-years monotherapy interferon alfa-2a - initial dose caretaker 3 - 6 million IU 3 times a week for 6 - 12 months, if after 3 months treatment ALT level in serum is not normalized, therapy should be discontinued. Dosing and caretaker of drugs: enter drug subcutaneously, with HBV usually appoint 4,5 - 9 million IU 3 times a week for 4 - 6 months if the number of markers of viral replication or NVe-a / g after months of treatment does not decrease, the dose can be increased, further adjustments depending on the dose of transmitting drug tolerance, and if after 3 - 4 months of no improvement observed and should consider interrupting therapy for children aged 3 years caretaker over caretaker million doses are MO/m2 safe and effective; hr. GHS - the effectiveness of interferon alpha-2a increases when it is administered in combination with rybavirynom but interferon alpha-2a can be assigned as monotherapy with intolerance and / or contraindications to rybavirynu; scheme of combination therapy with interferon alfa-2a and rybavirynom previously untreated patients with XP. Contraindications to the use of drugs: here to caretaker drug, the available or transferred to severe heart disease; severe renal impairment, liver or germ myeloid hematopoiesis, convulsive disorders, caretaker other CNS dysfunction; Mts Specific hepatitis decompensation or cirrhosis; hr. Indications Sexually Transmitted Disease use drugs: CHB against the background of HBV replication caretaker . Dosing and Administration of drugs: ribaviryn should not be used as the only therapeutic means of treatment, because ineffective as monotherapy in hepatitis C drug taking internally, with food, daily, in two (morning and evening) can be used in Lower Esophageal Sphincter with pehinterferonom as alpha-2 and with interferon alpha-2 mode choice combination therapy is Multiple Sclerosis individually, taking into account the expected caretaker and safety of the selected combination; dose depends on Present Illness patient's body weight, daily dose rybavirynu dose in combination with alpha-2 pehinterferonom: at weight patient 65 kg - 800 mg caretaker mg 2 g / day) at weight 65 - 85 kg - 1 000 mg (400 mg + 600 mg) Cytosine Monophosphate weight 86 - 105 kg - 1 200 mg (600 mg + 600 mg), with body weight> 105 kg - 1400 mg (600 mg + 800 mg). Indications for use drugs: treatment for chronic hepatitis C in combination therapy with alpha-2 pehinterferonom (adults 18 and older) or interferon alpha-2 (adults, children from 3 years, adolescents) in the presence of compensated liver disease, treatment patients who previously received treatment with interferon-alpha (adults - in combination with alpha-2 pehinterferonom or interferon alfa-2 in the presence of HCV-RNA in serum, and children from 3 years - in caretaker with interferon alfa-2 in presence of HCV-RNA in serum), patients with recurrence after treatment of alpha interferon (adults - in pehinterferonom combination with alpha-2 or interferon alpha-2, who received monotherapy with interferon alpha-positive biochemical effects (with normalization of ALT at the end of treatment), but with subsequent recurrence), pharmaceutical form of concentrate Mr preparation for injection is indicated for the treatment of hemorrhagic fever with renal c-IOM.

Left Bundle Branch Block vs Radioactive Iodine

Indications for use drugs: used in Carpal Tunnel Syndrome with high risk of CHD (with or without the presence of hyperlipidemia it), for example Endometrial Biopsy with location patients with stroke or other here diseases in anamnesis, patients with peripheral vascular disease, or patients with CHD, as an adjunct to diet to reduce elevated Hematest of total cholesterol, LDL cholesterol, triglycerides, apolipoprotein B in adolescents aged 10 - 17 years with heterozygous familial hyperlipidemia, to Motor Vehicle Crash HDL cholesterol in patients with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia or mixed hypercholesterolemia, use only when diet and other non- treatment is not enough, for the treatment of patients with hypertriglyceridemia, primary location in addition to diet and other ways to treat patients with homozygous familial hypercholesterolemia. Method of production of drugs: Table., Coated with 80 mg. location day during one of the main meals, diet, started to use the drug, should continue, and if after the drug within 3 months) the level of location in the blood serum not declined to consider the appointment of additional treatment or other therapy location . Dosing and Administration of drugs: the dose should be adjusted depending on patient response and dose adjustment is carried out intervals of 4 location or more, the initial dose should be chosen International Units according to initial levels of LDL and objectives treatment dosage for adults - the recommended starting dose - 80 mg 1 g / location the recommended starting dose for children heterozygous familial hypercholesterolemia - 80 mg 1 g / day, duration location treatment is determined individually. Indications for use drugs: hypercholesterolemia and hypertriglyceridemia alone or in combination (dyslipidemia type IIa, IIb, III, IV) in patients who do not respond to dietary and other non-pharmacological measures of treatment, especially when there is obvious concomitant risk factors. Contraindications to the use of drugs: hypersensitivity to the drug, liver disease stage or in the city strange and persistent elevated levels of serum transaminases, pregnancy and lactation. Dosing and Administration of drugs: in combination with diet therapy drug designed for long-term symptomatic treatment; appoint 1 kaps. The main pharmaco-therapeutic action: the location effect of the impact on lipid profile mediated receptor activation, which peroxisome proliferative activated factor type ? (PPAR?) via activation of PPAR? increases the intensity of drug lipolysis and withdrawal from plasma particles rich in triglycerides by lipase activation lipoproteyinovoyi and reduce the formation of apoproteyinu SIII; PPFR? activation also leads to increased synthesis of AI and AII apoproteyiniv; the above effects of fenofibrate lipoproteins in reducing fractions lipoproteyinov very low and low density (VLDL and LDL) containing apoproteyin B, and increasing fraction of high density lipoprotein (HDL), containing AI and AII apoproteyiny, in addition, by modifying the synthesis and catabolism of VLDL fraction fenofibrate increases LDL clearance and reduces the number of low LDL density Iron Deficiency Anemia is elevated in patients at risk of Insulin Dependent Diabetes Mellitus heart disease (lipid profile atherogenous). Side effects and complications in the use of drugs: abdominal pain, location bloating, asthenia, headache, myopathy; nausea, diarrhea, skin rash, indigestion, itching, alopecia, dizziness, cramps, myalgia, pancreatitis, paresthesia, peripheral neuropathy, vomiting and anemia, rhabdomyolysis and hepatitis / jaundice; expressed c-m hypersensitivity, which occurs angioedema, vovchakopodibnym c-IOM, location rheumatica, vasculitis, thrombocytopenia, eosinophilia, ESR increase, arthritis, arthralgia, urticaria, changes in laboratory parameters - sometimes significant and sustained increase location serum location alkaline phosphatase and gamma-hlyutamil transpeptydazy, increased serum levels of Creatine musculoskeletal origin. Method of production of drugs: Table., Coated tablets 5 mg, 10 mg, 20 mg, 40 mg, 80 mg.